Trump’s Secret Pharma Deals Threaten ‘Most‑Favored Nation’ Savings

When the Trump administration first floated the idea of tying Medicare’s drug payments to the lowest prices paid by a basket of 19 wealthy nations, the headlines were full of optimism – $26 billion in savings, a lifeline for patients, a big win against runaway prescription‑drug costs.

But the reality, as a new deep‑dive analysis shows, may be a lot less glittery. Behind the public fanfare, the White House has been quietly negotiating rebates with more than two dozen pharmaceutical companies. Those side‑door deals, the report argues, could chip away as much as 80 % of the projected savings.

The policy at the heart of the controversy is called “most‑favored‑nation” (MFN) pricing. In plain English, it would require drug makers to match the lowest price that any of the 19 reference countries pay for the same medicine. The administration rolled out two pilot programs to test the idea – GLOBE for Medicare Part B (injectable and infused drugs) and GUARD for Part D (the prescription drug benefit). Both pilots would levy extra rebates on companies whose U.S. prices climb above the international floor.

So where do the secret deals fit in? According to the analysis, several manufacturers have been offered tailored rebate structures that effectively sidestep the MFN rule. In exchange for vague promises of future market access or regulatory goodwill, they agree to give the government a modest kick‑back that falls short of the full price‑gap reduction the policy originally envisioned.

Critics say this approach defeats the purpose of MFN pricing. By allowing companies to negotiate separate, less‑stringent terms, the administration undermines the very leverage the program was supposed to wield. The result? The $26 billion figure, which was touted as a multi‑year win, could be slashed to a few billion – a dramatic shortfall that would leave many seniors still staring at sky‑high drug bills.

Supporters of the pilots argue that the deals are a pragmatic compromise. They claim that without any concessions, several big‑ticket drugs might never enter the programs at all, and that incremental rebates are better than nothing. Yet the analysis points out that the lack of transparency makes it hard to gauge whether these concessions truly serve Medicare’s interests or simply grease the wheels for pharma’s bottom line.

What comes next is still up in the air. Detailed rulemaking is slated for later this year, and lawmakers on Capitol Hill are already calling for hearings to shine a light on the private negotiations. For patients and policy wonks alike, the story is a reminder that behind every headline promise, the devil is often in the fine print – and sometimes, in a closed‑door meeting.